RecruitingPhase 2NCT02977780

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)


Sponsor

Patrick Wen, MD

Enrollment

460 participants

Start Date

Feb 9, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing personalized treatment strategies for glioblastoma (an aggressive type of brain tumor), where patients receive targeted therapies chosen based on specific features of their tumor after maximum surgical removal. **You may be eligible if...** - You have been diagnosed with glioblastoma or a related type of brain tumor (gliosarcoma), confirmed after surgery to remove as much of the tumor as possible - You may have had prior surgery but have not yet received chemotherapy or radiation - You are 18 years of age or older - Your overall health and ability to function is reasonably good (Karnofsky score of 60 or higher) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - Your tumor is primarily in the lower part of the brain (infratentorial area) - You have already received chemotherapy or radiation for this tumor - You have another active cancer - You are pregnant or breastfeeding - You have significant other health conditions that could interfere with treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTemozolomide

Temzolomide capsules

DRUGNeratinib

Neratinib tablets

DRUGQBS10072S

QBS10072S administered intravenously

DRUGAbemaciclib

Abemaciclib tablets

DRUGCC-115

CC-115 tablets


Locations(12)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Columbia University Medical Center

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Lifespan / Rhode Island Hospital

Providence, Rhode Island, United States

UT MD Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute

Salt Lake City, Utah, United States

University of Virginia Health System

Charlottesville, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02977780


Related Trials